North America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk An

North America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis, and Others), Therapeutic Application (Oncology, Infectious Diseases, Neurological Disorders, Autoimmune Diseases, Gynecological Disorders, Cardiovascular Diseases, Respiratory Disorders, and Others), and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization, and Others)

The North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031; it is estimated to register a CAGR of 8.0% from 2023 to 2031.

Expanding Range of Application of Pharmacokinetic Studies Fuels North America Pharmacokinetics Services Market

Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.

North America Pharmacokinetics Services Market Overview

The US accounts for the largest share of the North America pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021.

North America Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

North America Pharmacokinetics Services Market Segmentation

The North America pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. The US dominated the North America pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the North America pharmacokinetics services market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pharmacokinetics services market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America pharmacokinetics services market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.